Unilateral Pigmentary Retinopathy (UPR)

Unilateral Pigmentary Retinopathy (UPR) describes a retina-degenerating condition in one eye that looks and behaves like retinitis pigmentosa (RP), but with the other eye normal. The retina is the “film” at the back of the eye that senses light. In UPR, rod cells (for night and side vision) and later cone cells (for central and color vision) slowly lose function. On eye exam, doctors may see bone-spicule-like pigment, attenuated (thinned) retinal vessels, and a pale optic disc—changes similar to RP, but confined to one eye. People can notice night blindness, poor dark adaptation, tunnel vision, glare sensitivity, or later central blur if the macula is involved.

Unilateral pigmentary retinopathy means pigment-related scarring and degeneration in the retina of one eye only.

• “Unilateral” means one eye is affected while the other eye looks normal.

• “Pigmentary” refers to dark specks or clumps of pigment (natural color cells from the retinal pigment epithelium, or RPE) that move from their usual layer and collect inside the retina in a pattern doctors often call “bone-spicule” pigmentation.

• “Retinopathy” means disease or damage of the retina, the light-sensing layer at the back of the eye that sends signals to the brain so we can see.

In many people with pigmentary retinopathy, both eyes are involved (this is common in retinitis pigmentosa). But in true unilateral cases, only one eye shows the changes. This is rare. Sometimes a person seems to have one-sided disease at first, but the second eye shows signs years later (asymmetric or delayed involvement). Because of this, doctors often use careful follow-up over time before labeling a case as true unilateral.

What is happening inside the eye?

• The rods and cones (the retina’s light-sensing cells) and the retinal pigment epithelium (RPE) are injured or lost in a patchy way.

• When the RPE is disturbed, pigment cells migrate into the retina along blood vessels and form the bone-spicule pattern.

• Over time, the retinal vessels thin (arteriolar attenuation) and the optic disc (entry point of the optic nerve) can look waxy or pale, signs that the retina has lost function.

• The visual field (the area you can see when looking straight ahead) can shrink, often starting in the periphery (side vision) and moving inward.

• Night vision and dark adaptation (how quickly your eyes adjust in the dark) usually worsen early because rods—the cells used for dim light—are very sensitive to this kind of damage.

Unilateral pigmentary retinopathy is not a single disease. It is a final common appearance that can be caused by many different problems, including rare genetic effects in one eye, infections, inflammation, injury, toxic metals, radiation, or long-standing retinal detachment. The job of the clinician is to figure out which cause is behind the pigment changes, because the cause influences prognosis and what else needs to be treated.

---

Types

1. True Unilateral Retinitis Pigmentosa (mosaic form)
   In this rare type, a genetic change occurs only in cells of one eye (a “mosaic” or somatic mutation), so the affected eye looks like classic retinitis pigmentosa with bone-spicule pigment, blood vessel narrowing, and night vision problems, while the other eye stays normal even after years of follow-up.

2. Pseudo-Unilateral (Asymmetric) Pigmentary Retinopathy
   At first it looks like only one eye is affected, but the fellow eye shows subtle or delayed changes later. This is common early in some inherited diseases where the two eyes progress at different speeds.

3. Post-Inflammatory Unilateral Pigmentary Retinopathy
   Past uveitis or retinitis (inflammation of the retina/choroid) can leave pigment clumping and retinal thinning in one eye. The inflammation may have been infectious or autoimmune, and the pigment is a scar rather than a primary genetic degeneration.

4. Infectious Unilateral Pigmentary Retinopathy
   Some infections (for example, syphilis or toxoplasmosis) damage one eye and leave salt-and-pepper or spicule-like pigment after the infection quiets down. The other eye may remain normal.

5. Traumatic Pigmentary Retinopathy
   Blunt trauma, penetrating trauma, or shock waves to one eye can injure the retina and RPE, leading to permanent pigment migration.

6. Toxic Metal–Related Pigmentary Retinopathy (Siderosis/Chalcosis)
   A retained iron (siderosis bulbi) or copper (chalcosis) intraocular foreign body in one eye can poison the retina and RPE, creating pigment changes and progressive vision loss if not removed.

7. Radiation-Related Pigmentary Retinopathy
   Radiation therapy to one side of the head/face can cause radiation retinopathy in that eye, with capillary damage and secondary pigment migration over time.

8. Degeneration After Long-Standing Retinal Detachment
   A chronic retinal detachment in one eye starves the retina of nutrients and oxygen. After reattachment or even if it remains detached for long, the eye may show pigment clumping and retinal atrophy.

9. Vascular Sequelae with Pigment Migration
   Old retinal vein occlusion or severe ischemia (lack of blood flow) in one eye may lead to pigment migration as the retina thins and scars.

10. Paravenous or Sectoral Unilateral Patterns
    Pigmentary changes along veins (pigmented paravenous retinochoroidal atrophy) or in a sector of the retina can be one-sided and mimic unilateral retinitis pigmentosa.

---

Causes

1. Somatic (mosaic) mutation causing true unilateral retinitis pigmentosa
   A gene change happens only in cells that formed one eye. That eye acts like RP; the other remains normal even after long follow-up.

2. Asymmetric inherited retinitis pigmentosa with delayed fellow-eye involvement
   The disease is in your DNA, but one eye shows signs years before the other. Early on, it looks unilateral.

3. Previous infectious retinitis – Syphilis
   Syphilis can quietly damage the retina. After treatment, the eye may be left with salt-and-pepper or spicule-like pigmentation.

4. Previous infectious retinitis – Toxoplasmosis
   Toxoplasma can cause retinochoroiditis (retina + choroid inflammation). Healed lesions often have pigment clumps and scars.

5. Previous infectious retinitis – Tuberculosis (TB)
   Ocular TB can inflame the back of the eye, leaving pigmented scars and thinning in one eye.

6. Previous infectious retinitis – Viral (e.g., CMV in immunosuppressed)
   Cytomegalovirus can destroy retinal tissue in one eye; after healing, pigment migration marks the damaged areas.

7. Previous infectious retinitis – Rubella (congenital or acquired)
   Rubella can lead to salt-and-pepper fundus changes; sometimes these are more obvious in one eye.

8. Autoimmune uveitis
   The body’s immune system attacks eye tissues, causing inflammation, then scarring and pigment changes in one eye.

9. Sarcoidosis-related posterior uveitis
   Granulomas and inflammation from sarcoid can cause retinal/RPE injury, leaving pigment behind in one eye.

10. Radiation retinopathy (after orbital, sinus, or head/neck radiation)
    Radiation damages small vessels; over time the retina thins, and pigment migrates.

11. Blunt or penetrating ocular trauma
    A hit or a wound to the eye injures retina/RPE, leading to pigment clumps and vision changes.

12. Siderosis bulbi (retained iron foreign body)
    Iron is toxic to retinal cells. Without removal, progressive pigmentary degeneration and vision loss occur.

13. Chalcosis bulbi (retained copper foreign body)
    Copper also harms the retina and RPE, causing pigmentary changes and other signs like sunflower cataract.

14. Chronic retinal detachment
    Long separation of the retina from its blood supply leads to cell loss and pigment migration after healing or repair.

15. Old retinal vein occlusion (ischemic)
    Poor blood flow damages the retina and can leave pigment scarring.

16. Paraneoplastic autoimmune retinopathy
    Rare immune attack triggered by a distant cancer can damage retinal cells; sometimes one eye appears worse.

17. Drug-related retinal toxicity (less often unilateral)
    Most toxicities (e.g., chloroquine) are bilateral, but very asymmetric damage can make one eye appear unilateral early.

18. Ocular toxocariasis
    A parasite can inflame one eye and leave pigmented scars after the active phase resolves.

19. Pigmented paravenous retinochoroidal atrophy
    A pattern of pigment along veins; sometimes it looks one-sided, especially early or if subtle in the other eye.

20. Vascular inflammatory diseases (e.g., Behçet disease) with focal scarring
    Inflammation of retinal vessels can lead to localized damage and pigment migration centered in one eye.

---

Symptoms

1. Night blindness (nyctalopia)
   Trouble seeing in dim rooms or at night because the rod cells are damaged.

2. Peripheral vision loss (constriction of visual field)
   Feels like tunnel vision; you bump into things on the side or miss objects coming from the edges.

3. Slow dark adaptation
   After bright light, it takes a long time to see in the dark again—much longer than other people.

4. Glare and light sensitivity (photophobia)
   Bright lights feel uncomfortable; you squint or need sunglasses even in moderate light.

5. Reduced contrast sensitivity
   Gray letters on a gray background are hard to read; faces or steps are harder to distinguish.

6. Flashes of light (photopsia)
   You see brief sparkles or flickers in the side vision, especially in dim light.

7. Floaters
   Small moving spots or threads, often due to old inflammation or changes in the gel (vitreous) inside the eye.

8. Blurred central vision (if the macula is involved)
   Reading and recognizing faces become harder if pigmentary damage reaches the macula (central retina).

9. Color vision changes
   Colors may look faded or less vibrant, especially blues and greens, if cones are affected.

10. Difficulty driving at night
    Headlights and darkness together become challenging; you may avoid night driving.

11. Poor vision in dim restaurants or movie theaters
    You need extra time to adapt, and moving around in low light is unsafe or uncomfortable.

12. Loss of depth judgment
    With one eye affected, your stereovision can be off, making steps and curbs feel tricky.

13. Headaches or eyestrain
    You work harder to see, especially in low light, and this effort can cause discomfort.

14. Occasional eye redness or mild ache
    More common if the original cause was inflammation or trauma; not typical in pure degenerations.

15. No symptoms at all (incidental finding)
    Some people notice nothing until a routine exam shows pigment changes in one eye.

---

Diagnostic Tests

A) Physical Exam

1. General medical and systemic exam
   The doctor looks for clues outside the eye, such as skin rashes, joint swelling, lung issues, or signs of infection or autoimmune disease. These clues can guide testing for causes like sarcoid, syphilis, or TB.

2. Pupil exam with RAPD check (Relative Afferent Pupillary Defect)
   The doctor shines a light to see if pupils react equally. A RAPD suggests the retina or optic nerve in the affected eye isn’t sending normal signals, supporting that the problem is real and unilateral.

3. Slit-lamp exam of the front of the eye
   A microscope checks for inflammation (cells/flare), old trauma signs, cataract (which can follow inflammation, radiation, or metal toxicity), and other changes that support or narrow the cause.

B) Manual / Office / Psychophysical Tests

4. Best-corrected visual acuity (distance and near)
   Measures sharpness of sight with the best glasses correction. Tracking this over time shows progression or stability.

5. Color vision testing (Ishihara or similar)
   Simple dot-plate tests look for color loss, which can happen if cones or inner retina are affected.

6. Visual field testing (confrontation and formal perimetry)
   Confrontation fields are a quick office screen; Goldmann or Humphrey perimetry maps the field precisely, often showing ring scotomas or peripheral constriction.

7. Dark adaptation testing (psychophysical)
   Measures how quickly vision recovers in the dark after bright light. Prolonged dark adaptation supports rod dysfunction typical of pigmentary retinopathy.

8. Contrast sensitivity and photostress recovery
   Tests how well you see faint patterns and how quickly vision returns after a bright light stress. Poor performance suggests retinal dysfunction even when regular acuity looks okay.

C) Lab & Pathological Tests

9. Syphilis testing (non-treponemal + treponemal)—e.g., RPR/VDRL and TP-PA/FTA-ABS
   Rules in or out syphilitic retinopathy, a classic mimic that can leave salt-and-pepper or spicule-like pigment.

10. Toxoplasma serology (IgG/IgM)
    Helps identify past or recent toxoplasma infection that can cause unilateral retinal scars with pigment.

11. TB screening (IGRA) with clinical correlation
    Positive interferon-gamma release assay plus symptoms or imaging can support ocular TB as a cause.

12. Sarcoid markers (ACE, lysozyme ± serum calcium)
    Elevated levels support sarcoidosis, which can inflame the eye and lead to pigmentary scarring.

13. HIV testing (when risk factors present)
    Important if CMV retinitis or other opportunistic infections are suspected, because these can leave pigmentary changes after healing.

Other labs sometimes used based on history: autoimmune panels (ANA/ANCA), paraneoplastic antibodies (e.g., anti-recoverin), and genetic testing for inherited retinal disease. These are tailored to the individual.

D) Electrodiagnostic Tests

14. Full-field electroretinogram (ffERG)
    Measures the electrical response of the entire retina to flashes of light. In unilateral pigmentary retinopathy, the affected eye’s responses are reduced or absent, while the other eye is normal. This is strong, objective evidence that the disease is real and one-sided.

15. Multifocal ERG (mfERG)
    Maps local retinal function across the posterior pole. It shows patches of weak or absent responses that match the areas of pigment and thinning seen on imaging.

16. Electro-oculogram (EOG)
    Evaluates RPE function by measuring changes in eye electrical potential with light/dark cycles. Abnormal results support RPE dysfunction that goes with pigmentary disease.

E) Imaging Tests

17. Optical Coherence Tomography (OCT)
    OCT is a non-contact scan that shows retinal layers in cross-section. It can reveal loss of the outer retina (ellipsoid zone disruption), RPE thinning, cystoid macular edema, or epiretinal membrane. These details explain vision loss and help track progression.

18. Fundus Autofluorescence (FAF)
    FAF maps the natural glow from lipofuscin in the RPE. Hypo-autofluorescent areas show dead or missing RPE, and hyper-autofluorescent rings can mark stressed tissue at the border of disease. FAF patterns often match the bone-spicule and field loss.

19. Fluorescein Angiography (FA)
    A dye test that shows retinal blood flow. It can uncover capillary non-perfusion, leakage from inflamed vessels, or neovascular changes in radiation or vascular causes. FA helps separate genetic-like patterns from inflammatory or ischemic patterns.

20. CT or MRI of the orbits/eye (when foreign body or tumor suspected)
    CT is excellent for metal foreign bodies (iron/copper) that cause siderosis/chalcosis. MRI is better for soft tissues (not used if metal is suspected). These scans are crucial when trauma history or signs point to toxic metal or mass lesion.

Non-Pharmacological Treatments (Therapies & Others)

Each item includes description, purpose, mechanism in plain language.

1. Low-vision rehabilitation
   Description: Structured training with a low-vision specialist, plus tools (magnifiers, telescopic glasses, contrast enhancements).
   Purpose: Make reading, mobility, school/work tasks easier despite vision loss.
   Mechanism: Compensates for lost peripheral/low-light function by optimizing remaining central vision, magnifying print, boosting contrast, and teaching practical strategies.

2. Orientation & mobility (O&M) training
   Description: Step-by-step coaching for safe navigation indoors/outdoors, including white cane skills if needed.
   Purpose: Improve independence and reduce falls in people with tunnel vision or night blindness.
   Mechanism: Builds map-making, scanning, and pathfinding habits that compensate for lost peripheral vision.

3. Task lighting & glare control
   Description: Use bright, adjustable lamps, matte surfaces, anti-glare filters, and hats/visors.
   Purpose: Reduce glare, improve contrast, and help reading/sewing/computer work.
   Mechanism: Increases signal-to-noise for retinal cells that struggle in poor light or with glare.

4. Contrast optimization
   Description: High-contrast print, bold markers, black-on-white or white-on-black modes, large-print materials.
   Purpose: Faster recognition of text and objects.
   Mechanism: Enhances edge detection for weakened photoreceptors and visual pathways.

5. Electronic magnification (CCTV, tablets, e-readers)
   Description: Cameras or apps that enlarge text/images and adjust brightness/contrast.
   Purpose: More comfortable reading/learning/work.
   Mechanism: Digital zoom + contrast boosts make small letters recognizably large and sharp.

6. Screen readers & accessibility software
   Description: Text-to-speech, larger cursors, voice assistants, high-contrast UI modes.
   Purpose: Keep computer/phone use feasible.
   Mechanism: Offloads visual load to audio and enlarges key UI elements.

7. UV-blocking and blue-filter spectacles
   Description: Glasses with 100% UV protection; optional blue-filter tints for glare.
   Purpose: Protect retina from phototoxic stress and reduce discomfort.
   Mechanism: Filters UV and short-wavelength light, lowering oxidative stress and glare.

8. Nighttime environmental adjustments
   Description: Motion-sensor night lights, reflective tape on steps, decluttered walkways.
   Purpose: Prevent trips/falls when rods are struggling in low light.
   Mechanism: Improves visual cues and orientation in dim conditions.

9. Driving safety counseling
   Description: Honest talk about legal vision standards, night driving risks, and alternatives.
   Purpose: Protect patient and public safety; reduce anxiety.
   Mechanism: Aligns functional limits with safe behaviors.

10. Fatigue management & visual breaks
    Description: Pacing tasks, 20-20-20 breaks, task batching in optimal lighting hours.
    Purpose: Maintain productivity and comfort.
    Mechanism: Reduces visual strain and glare/time-on-task burden.

11. Anti-oxidant-rich diet (see foods below)
    Description: Leafy greens, colorful vegetables, oily fish, nuts.
    Purpose: Support retinal metabolism and overall eye health.
    Mechanism: Provides omega-3s, lutein/zeaxanthin, vitamins, minerals for photoreceptor support.

12. Cardiometabolic fitness
    Description: Regular moderate exercise (walking, cycling).
    Purpose: Support retinal perfusion and systemic health.
    Mechanism: Improves vascular function, lowers inflammation and oxidative stress.

13. Smoking cessation
    Description: Stop cigarettes and vaping nicotine.
    Purpose: Protect retinal microcirculation and reduce oxidative injury.
    Mechanism: Eliminates toxic oxidative load and vasoconstriction.

14. Alcohol moderation
    Description: Keep intake low; avoid binge drinking.
    Purpose: Prevent nutritional deficits and neurotoxicity that can worsen vision.
    Mechanism: Reduces oxidative and metabolic stress on neurons.

15. Protective eyewear for sports/work
    Description: Impact-resistant goggles where trauma risk exists.
    Purpose: Prevent eye injuries that could worsen a compromised retina.
    Mechanism: Physical barrier against blunt/penetrating trauma.

16. Systemic health optimization
    Description: Manage diabetes, blood pressure, lipids, sleep apnea.
    Purpose: Support retinal blood flow and reduce edema risk.
    Mechanism: Stabilizes vascular and inflammatory milieu.

17. Education & support groups
    Description: Patient education, counseling, peer groups.
    Purpose: Coping skills, adherence, and mental health.
    Mechanism: Lowers stress and builds problem-solving habits that preserve function.

18. Photophobia management
    Description: Tinted clip-ons, photochromic lenses, brimmed hats.
    Purpose: Reduce light sensitivity and headaches.
    Mechanism: Limits light scatter and short-wavelength glare.

19. Workplace/school accommodations
    Description: Larger monitors, screen readers, seating nearer to displays, extended time.
    Purpose: Maintain performance and access.
    Mechanism: Matches task demands to visual capacity.

20. Regular structured follow-up
    Description: Eye checks every 6–12 months (or sooner if changes), with OCT/fields as needed.
    Purpose: Catch treatable issues early (macular edema, cataract, CNV).
    Mechanism: Surveillance enables timely intervention.

---

Drug Treatments

Important: There is no medicine that cures UPR. Drugs are used to treat complications (like macular edema), to control inflammation if present, or to manage associated conditions. Doses below are typical examples—final choices must be set by your ophthalmologist after examining you.

1. Topical carbonic anhydrase inhibitors (CAIs) – dorzolamide 2%, brinzolamide 1%
   Class: Carbonic anhydrase inhibitor (topical).
   Example dose/time: 1 drop 3×/day (varies).
   Purpose: Treat cystoid macular edema (CME) that can occur in pigmentary retinopathies.
   Mechanism: Improves fluid transport across the retinal pigment epithelium (RPE), helping dry macular cysts.
   Key side effects: Eye irritation, bitter taste; rare corneal decompensation in susceptible corneas.

2. Oral carbonic anhydrase inhibitor – acetazolamide
   Class: Carbonic anhydrase inhibitor (systemic).
   Example dose/time: 250 mg 2–3×/day (short courses often).
   Purpose: Alternative/adjunct for CME.
   Mechanism: Similar to topical CAIs but with systemic effect; enhances retinal fluid resorption.
   Key side effects: Tingling, fatigue, kidney stones, metabolic acidosis, sulfonamide allergy concerns.

3. Topical corticosteroids – prednisolone acetate 1%, loteprednol
   Class: Corticosteroid (topical).
   Example dose/time: 1 drop 2–4×/day, then taper (short courses).
   Purpose: If inflammation contributes to edema or uveitis.
   Mechanism: Anti-inflammatory; reduces vascular permeability.
   Key side effects: Eye pressure rise, cataract with long use, infection risk.

4. Periocular/intravitreal corticosteroid – triamcinolone; implant dexamethasone (Ozurdex)
   Class: Corticosteroid (local injection/implant).
   Dose/time: Triamcinolone commonly 1–4 mg intravitreal; dexamethasone 0.7 mg implant every several months as needed.
   Purpose: Persistent CME unresponsive to drops.
   Mechanism: Potent local anti-inflammatory, reduces capillary leak.
   Key side effects: Intraocular pressure rise, cataract progression, infection risk.

5. Intravitreal anti-VEGF – bevacizumab 1.25 mg, ranibizumab 0.5 mg, aflibercept 2 mg
   Class: Vascular endothelial growth factor inhibitors.
   Dose/time: Given intravitreal at 4–8-week intervals as needed.
   Purpose: Rare choroidal neovascularization (CNV) or vascular leakage threatening the macula.
   Mechanism: Blocks VEGF, reducing abnormal vessel growth/leak.
   Key side effects: Injection risks (infection, pressure spike), rare systemic effects.

6. Nonsteroidal anti-inflammatory eye drops – nepafenac, bromfenac, ketorolac
   Class: Topical NSAID.
   Dose/time: 1 drop 1–3×/day depending on agent.
   Purpose: Mild adjunct for CME or post-op inflammation.
   Mechanism: COX inhibition → less prostaglandin-mediated leakage.
   Key side effects: Surface irritation; rare corneal melt with prolonged/frequent use on compromised corneas.

7. Systemic corticosteroids – prednisone
   Class: Corticosteroid (oral).
   Dose/time: Example 0.5–1 mg/kg/day short-term with taper if a clear inflammatory driver is proven.
   Purpose: Control active uveitis/retinitis mimicking RP in acquired unilateral cases.
   Mechanism: Broad immune suppression; reduces retinal vascular leak.
   Key side effects: Weight gain, blood sugar rise, mood changes, infection risk, osteoporosis, gastric upset.

8. Steroid-sparing immunomodulators – e.g., methotrexate, mycophenolate mofetil, azathioprine
   Class: Disease-modifying immunosuppressants.
   Dose/time: Specialist-titrated (e.g., methotrexate 10–25 mg weekly with folate).
   Purpose: For recurrent noninfectious uveitis/retinitis causing RP-like damage.
   Mechanism: Tames immune over-activity to prevent further retinal injury.
   Key side effects: Liver/blood toxicity (labs needed), infection risk, teratogenicity (drug-dependent).

9. Antimicrobials when infectious cause proven – tailored therapy
   Class: Antibiotic/antiviral/antiparasitic matched to the organism (e.g., penicillin for syphilis, pyrimethamine-sulfadiazine for toxoplasmosis, acyclovir/valacyclovir for herpetic disease).
   Dose/time: Diagnosis-specific per guidelines.
   Purpose: Stop active infection that can produce unilateral pigmentary scars.
   Mechanism: Eradicates pathogen, preventing further retinal damage.
   Key side effects: Drug-specific; monitoring by the treating physician is essential.

10. Manage associated ocular hypertension/glaucoma – timolol, latanoprost, etc.
    Class: IOP-lowering agents.
    Dose/time: Standard glaucoma regimens individualized.
    Purpose: Protect optic nerve if IOP elevated, especially after steroids.
    Mechanism: Reduces aqueous production or increases outflow, lowering eye pressure.
    Key side effects: Drug-specific (e.g., timolol can affect heart/lungs; prostaglandins can darken iris/lashes).

---

Dietary Molecular Supplements

Evidence varies; supplements do not cure UPR. They may support retinal metabolism or overall eye health. Avoid megadoses without supervision.

1. Omega-3 DHA/EPA (e.g., fish oil)
   Dose: Often 500–1000 mg/day combined DHA+EPA; dietary oily fish 2–3×/week.
   Function/Mechanism: Photoreceptor membrane support, anti-inflammatory lipid mediators.

2. Lutein
   Dose: 10 mg/day (commonly studied range 10–20 mg).
   Function/Mechanism: Macular pigment antioxidant, filters blue light, reduces oxidative stress.

3. Zeaxanthin
   Dose: 2 mg/day (often combined with lutein).
   Function/Mechanism: Works with lutein to stabilize macular pigment and scavenge free radicals.

4. Astaxanthin
   Dose: 4–12 mg/day.
   Function/Mechanism: Potent carotenoid antioxidant; may support mitochondrial resilience.

5. Coenzyme Q10 (ubiquinone) or Idebenone
   Dose: CoQ10 100–300 mg/day; idebenone is prescription in some regions.
   Function/Mechanism: Mitochondrial electron transport cofactor; may aid cellular energy.

6. Alpha-lipoic acid
   Dose: 200–600 mg/day.
   Function/Mechanism: Redox recycling of other antioxidants; chelates metals; supports mitochondria.

7. Vitamin D3
   Dose: 1000–2000 IU/day typical; target healthy serum levels.
   Function/Mechanism: Immune modulation and neurotrophic support.

8. Vitamin A (retinol/retinyl palmitate) – caution
   Dose: If considered at all, low to moderate only, and avoid in pregnancy and liver disease.
   Function/Mechanism: Visual cycle cofactor; historical RP studies exist, but risks (liver toxicity, teratogenicity) mean specialist guidance is mandatory.
   Note: High-dose vitamin A is not routine for UPR.

9. Resveratrol (polyphenol)
   Dose: 100–250 mg/day (supplemental).
   Function/Mechanism: Sirtuin activation, anti-inflammatory/antioxidant pathways.

10. Zinc (with copper balance)
    Dose: 10–25 mg/day zinc with 1–2 mg copper to avoid deficiency.
    Function/Mechanism: Cofactor in antioxidant enzymes; supports retinal metabolism.
    Caution: Excess zinc can cause copper deficiency and anemia.

---

Regenerative / stem cell” drugs

There is no approved regenerative or stem-cell drug for UPR. The items below are research directions. Not recommended outside controlled trials. No standard dosing for UPR.

1. Mesenchymal stem cell (MSC)–based intravitreal/subretinal therapy
   Function: Attempt to secrete neurotrophic factors and modulate inflammation.
   Mechanism: Paracrine support to photoreceptors/RPE.
   Status: Trials only; risks include inflammation, membrane formation.

2. Retinal progenitor cell transplantation
   Function: Try to replace/support dying photoreceptors.
   Mechanism: Engraftment and trophic signaling.
   Status: Early-phase trials; long-term benefit/safety unknown.

3. RPE cell therapy (e.g., iPSC-derived RPE)
   Function: Replace/support RPE to enhance photoreceptor survival.
   Mechanism: Subretinal monolayer metabolic and phagocytic support.
   Status: Trials for selected retinal diseases, not UPR-specific.

4. cGMP-retinal implant microchips / prostheses
   Function: Bypass damaged photoreceptors with electronic stimulation.
   Mechanism: Microelectrodes stimulate inner retina.
   Status: Limited availability; research/legacy devices; not disease-modifying.

5. Neurotrophic factors (e.g., CNTF) delivery
   Function: Neuroprotection to slow photoreceptor death.
   Mechanism: Trophic signaling via implanted reservoirs/gene vectors.
   Status: Mixed results; trial-only.

6. Gene therapy (vector-based) for defined mutations
   Function: Replace or edit a known defective gene.
   Mechanism: AAV vectors deliver gene copies to target cells.
   Status: Approved for specific biallelic RPE65 disease (bilateral RP variant), not for typical UPR; investigational otherwise.

---

Surgeries/Procedures

1. Cataract surgery (phacoemulsification with IOL)
   Procedure: Remove cloudy lens, implant clear intraocular lens.
   Why done: Posterior subcapsular cataracts are common in pigmentary retinopathies and worsen glare/blur. Restores clarity and improves function.

2. Pars plana vitrectomy for epiretinal membrane (ERM) or vitreomacular traction
   Procedure: Micro-incision removal of vitreous/ERM peel.
   Why done: If traction or membranes distort the macula, surgery can improve or stabilize central vision.

3. Laser retinopexy for retinal breaks
   Procedure: Laser “welds” around a tear.
   Why done: Prevent retinal detachment if symptomatic breaks are detected.

4. Intravitreal injection procedures (anti-VEGF or steroid)
   Procedure: Office-based sterile injection.
   Why done: Treat CNV or refractory CME threatening central vision.

5. Retinal prosthesis/microchip implantation (selected centers)
   Procedure: Implant electronic array (subretinal/epiretinal).
   Why done: For end-stage vision in some degenerations, to provide rudimentary light perception. Availability is limited and evolving.

---

Preventions

1. Protect the healthy eye with UV-blocking eyewear and trauma protection.

2. Prompt treatment of eye infections/uveitis to prevent RP-like scarring.

3. Control systemic inflammation (autoimmune disease management).

4. Review medications with your doctor to avoid retinal toxins when possible.

5. Stop smoking to reduce oxidative and vascular stress.

6. Manage blood pressure, diabetes, lipids for vascular stability.

7. Use proper lighting and contrast to prevent accidents and eye strain.

8. Adhere to follow-up for early detection of CME, CNV, or cataract.

9. Vaccination & infection prevention per medical guidance (systemic health protects eyes).

10. Family/genetic counseling if any hereditary pattern is suspected, to plan monitoring.

---

When to see a doctor

Seek urgent ophthalmic care now if you notice:

• Sudden vision drop, a dark curtain, or new flashes/floaters (possible retinal tear/detachment).

• Eye pain, redness, light sensitivity, or pus (possible uveitis/infection).

• Distortion or central blur (possible CME/CNV).

Routine follow-up: typically every 6–12 months (or as advised), including visual fields, OCT, and review of the fellow eye.

---

What to eat & what to avoid

What to eat (supportive, whole-food focus):

1. Leafy greens (spinach, kale) – lutein/zeaxanthin.

2. Oily fish (salmon, sardines, mackerel) – omega-3 DHA/EPA.

3. Colorful vegetables (carrots, peppers, beets) – antioxidants.

4. Citrus & berries – vitamin C and polyphenols.

5. Eggs – bioavailable lutein/zeaxanthin.

6. Nuts & seeds (walnuts, flax, chia) – healthy fats and minerals.

7. Legumes – fiber and micronutrients.

8. Whole grains – steadier glucose for vascular health.

9. Olive oil – monounsaturated fats and polyphenols.

10. Adequate water – overall metabolic support.

What to limit/avoid:

1. Smoking & secondhand smoke – retinal toxin.

2. Ultra-processed foods high in trans/saturated fats – oxidative stress.

3. Excess sugar/sugary drinks – vascular/inflammatory load.

4. Excess salt (especially if on steroids) – fluid/pressure concerns.

5. Frequent deep-fried foods – aldehydes/oxidants.

6. Heavy alcohol – neurotoxicity/nutrition deficits.

7. Megadose supplements without supervision – toxicity risks (e.g., vitamin A).

8. Unverified “miracle cures” – risk of harm and false hope.

9. High-glare eating environments (bright overhead lights) – symptom worsening.

10. Poor hydration – systemic fatigue can worsen visual function.

---

Frequently Asked Questions (FAQs)

1. Is UPR the same as RP?
   UPR looks like RP but confined to one eye. RP is usually bilateral. UPR may be truly unilateral or reflect severe asymmetry or past unilateral injury/inflammation.

2. Will my other eye go bad too?
   Often the fellow eye stays normal, but doctors monitor it over time. If it remains normal after years, true unilateral disease is more likely.

3. Can UPR be cured?
   Not currently. Care focuses on protecting the healthy eye, treating complications, and maximizing function with low-vision tools.

4. Can glasses fix UPR?
   Glasses fix refractive errors (blur) but cannot reverse retinal degeneration. They still help optimize remaining vision.

5. What causes UPR?
   Sometimes unknown; sometimes infections, inflammation, trauma, or vascular insults leave RP-like scarring. Rarely, mosaic genetic change may be involved.

6. How fast does it progress?
   Highly variable. Some remain stable for years; others slowly lose more peripheral vision. Regular follow-up is key.

7. Will I go completely blind?
   Complete blindness is uncommon; many retain some central or navigational vision, especially with rehabilitation.

8. Is driving safe?
   Depends on visual acuity, fields, and glare sensitivity. Doctors evaluate against legal standards; night driving is often difficult.

9. Do supplements help?
   They may support retinal metabolism, but no supplement cures UPR. Avoid megadoses; discuss choices with your doctor.

10. Should I try vitamin A?
    Only under specialist guidance due to toxicity/ pregnancy risks and mixed evidence. It is not routine for UPR.

11. What about stem cells or gene therapy?
    Experimental for UPR. Participate only in regulated clinical trials.

12. Can surgery help?
    Surgery helps complications (cataract, membranes, retinal breaks). It does not cure the underlying degeneration.

13. Why do I get glare and trouble at dusk?
    UPR affects rod cells first, causing night blindness and glare sensitivity. Lighting strategies and tints help.

14. How can I keep working or studying?
    Use accessibility tech, low-vision aids, and accommodations (bigger screens, screen readers, extra time). Low-vision specialists can set you up.

15. How often should I be checked?
    Commonly every 6–12 months, sooner if any new symptoms appear (flashes, floaters, curtain, central blur).

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 29, 2025.

PDF Document For This Disease Conditions References